|
US4221584A
(en)
|
1979-02-09 |
1980-09-09 |
Chevron Research Company |
Herbicidal and plant-growth-regulating N-(heterocyclyl)-methylacetanilides
|
|
US4735961A
(en)
|
1984-05-07 |
1988-04-05 |
Merck & Co., Inc. |
Oxazoles and thiazoles containing an aminohydroxypropoxyphenyl moiety
|
|
WO1996022997A1
(en)
*
|
1995-01-27 |
1996-08-01 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
|
WO1996031598A1
(en)
|
1995-04-06 |
1996-10-10 |
Regeneron Pharmaceuticals, Inc. |
Tie-2 ligands, methods of making and uses thereof
|
|
US20030040463A1
(en)
|
1996-04-05 |
2003-02-27 |
Wiegand Stanley J. |
TIE-2 ligands, methods of making and uses thereof
|
|
AU5154098A
(en)
|
1996-10-31 |
1998-05-22 |
Duke University |
Soluble tie2 receptor
|
|
US5980929A
(en)
|
1998-03-13 |
1999-11-09 |
Johns Hopkins University, School Of Medicine |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
|
|
US5919813C1
(en)
|
1998-03-13 |
2002-01-29 |
Univ Johns Hopkins Med |
Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
|
|
PT1165115E
(pt)
|
1999-03-26 |
2003-10-31 |
Univ California |
Modulacao da permeabilidade vascular por meio dos activadores do receptor tie2
|
|
US6455035B1
(en)
|
1999-03-26 |
2002-09-24 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
|
NZ536196A
(en)
|
2000-06-23 |
2006-12-22 |
Schering Ag |
Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
|
|
US7052695B2
(en)
|
2001-10-25 |
2006-05-30 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of treating hypertension
|
|
ES2290439T3
(es)
|
2002-02-25 |
2008-02-16 |
Eli Lilly And Company |
Moduladores del receptor activado del proliferador de peroxisomas.
|
|
AU2003229627A1
(en)
|
2002-04-08 |
2003-10-20 |
Max-Planck-Gesellschaft Zur |
Ve-ptp as regulator of ve-cadherin mediated processes or disorders
|
|
WO2003090686A2
(en)
|
2002-04-25 |
2003-11-06 |
University Of Connecticut Health Center |
Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
|
|
US7507568B2
(en)
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
|
US7226755B1
(en)
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
|
US6930117B2
(en)
|
2002-11-09 |
2005-08-16 |
The Procter & Gamble Company |
N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
|
|
US6946479B2
(en)
|
2002-11-09 |
2005-09-20 |
The Procter & Gamble Company |
N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
|
LT2653465T
(lt)
|
2004-03-15 |
2016-09-12 |
Janssen Pharmaceutica Nv |
Opioidinio receptoriaus moduliatoriai
|
|
WO2005089755A1
(en)
|
2004-03-18 |
2005-09-29 |
R-Tech Ueno, Ltd. |
Aqueous composition comprising thiazole derivative
|
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
WO2006014729A2
(en)
|
2004-07-20 |
2006-02-09 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
|
KR100980693B1
(ko)
|
2004-09-28 |
2010-09-07 |
(주) 에이프로젠 |
꼬인 코일형 키메라분자를 유효성분으로 하는 발기부전 치료제
|
|
BRPI0519596B1
(pt)
|
2004-12-21 |
2022-01-18 |
Astrazeneca Ab |
Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
|
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
|
US7893040B2
(en)
|
2005-07-22 |
2011-02-22 |
Oculis Ehf |
Cyclodextrin nanotechnology for ophthalmic drug delivery
|
|
WO2007033216A2
(en)
|
2005-09-12 |
2007-03-22 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
|
CA2633211A1
(en)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
|
|
AU2007237096C1
(en)
|
2006-04-07 |
2012-12-13 |
EyePoint, Inc. |
Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
|
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7795444B2
(en)
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US20130023542A1
(en)
|
2006-06-27 |
2013-01-24 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
PT2076290T
(pt)
|
2006-10-27 |
2017-01-17 |
Sunnybrook Health Sciences Center |
Agonistas de tie 2 multiméricos e utilizações dos mesmos na estimulação da angiogénese
|
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
|
WO2009105774A2
(en)
|
2008-02-21 |
2009-08-27 |
Sequoia Pharmaceuticals, Inc. |
Amino acid inhibitors of cytochrome p450
|
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
|
SG10201702247SA
(en)
|
2009-01-12 |
2017-04-27 |
Aerpio Therapeutics Inc |
Methods for treating vascular leak syndrome
|
|
BRPI1012302A2
(pt)
|
2009-03-03 |
2015-09-22 |
Alcon Res Ltd |
composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho
|
|
MX2011008680A
(es)
|
2009-03-03 |
2011-09-08 |
Alcon Res Ltd |
Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
|
|
MY160399A
(en)
|
2009-07-06 |
2017-03-15 |
Aerpio Therapeutics Inc |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
|
EP3698794A1
(en)
|
2009-11-06 |
2020-08-26 |
Aerpio Therapeutics, Inc. |
Compositions and methods for treating colitis
|
|
US20110319455A1
(en)
|
2010-04-19 |
2011-12-29 |
Bruce Steven Klein |
Antifungal Treatment
|
|
WO2012009288A2
(en)
|
2010-07-12 |
2012-01-19 |
Threshold Pharmaceuticals, Inc. |
Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
|
|
US20120129847A1
(en)
|
2010-10-07 |
2012-05-24 |
Kevin Gene Peters |
Compositions and methods for treating ocular edema, neovascularization and related diseases
|
|
US20180092883A1
(en)
|
2010-10-07 |
2018-04-05 |
Aerpio Therapeutics, Inc. |
Phosphatase inhibitors for treating ocular diseases
|
|
CN103249422A
(zh)
|
2010-12-02 |
2013-08-14 |
丸善制药株式会社 |
Tie2活化剂、血管内皮生长因子抑制剂、血管生成抑制剂、血管成熟剂、血管正常化剂及血管稳定剂、以及药物组合物
|
|
AU2012323856B2
(en)
|
2011-10-13 |
2017-05-25 |
EyePoint, Inc. |
Methods for treating Vascular Leak Syndrome and cancer
|
|
EP3501536B1
(en)
|
2011-10-13 |
2025-12-24 |
EyePoint Pharmaceuticals, Inc. |
Treatment of ocular disease
|
|
US20130190324A1
(en)
|
2011-12-23 |
2013-07-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Topical ocular drug delivery
|
|
WO2013155512A2
(en)
|
2012-04-13 |
2013-10-17 |
The Johns Hopkins University |
Treatment of ischemic retinopathies
|
|
LT3495387T
(lt)
|
2012-07-13 |
2021-11-25 |
Roche Glycart Ag |
Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
|
|
PT2880167T
(pt)
|
2012-07-31 |
2018-07-23 |
Univ Texas |
Métodos e composições para a indução in vivo da formação de células beta pancreáticas
|
|
MY177912A
(en)
|
2012-10-11 |
2020-09-25 |
Ascendis Pharma Ophthalmology Div A/S |
Vegf neutralizing prodrugs for the treatment of ocular conditions
|
|
EP2916827B1
(en)
|
2012-11-08 |
2020-06-10 |
Clearside Biomedical Inc. |
Methods for the treatment of ocular disease in human subjects
|
|
US20150290235A1
(en)
|
2012-11-23 |
2015-10-15 |
Ab Science |
Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
|
|
US20150050277A1
(en)
|
2013-03-15 |
2015-02-19 |
Aerpio Therapeutics Inc. |
Compositions and methods for treating ocular diseases
|
|
AU2014233363B2
(en)
*
|
2013-03-15 |
2017-06-29 |
EyePoint, Inc. |
Compositions, formulations and methods for treating ocular diseases
|
|
DK2983695T3
(da)
|
2013-04-11 |
2019-09-02 |
Sunnybrook Res Inst |
Fremgangsmåder, anvendelser og sammensætninger af tie2- agonister
|
|
WO2014203183A1
(en)
|
2013-06-20 |
2014-12-24 |
Novartis Ag |
Use of a vegf antagonist in treating macular edema
|
|
JP2016522249A
(ja)
|
2013-06-20 |
2016-07-28 |
ノバルティス アーゲー |
脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
|
|
US20160151410A1
(en)
|
2013-07-02 |
2016-06-02 |
The Trustees Of Columbia University In The City Of New York |
Clearance of bioactive lipids from membrane structures by cyclodextrins
|
|
EP3019527A2
(en)
|
2013-07-11 |
2016-05-18 |
Novartis AG |
Use of a vegf antagonist in treating retinopathy of prematurity
|
|
KR20160029794A
(ko)
|
2013-07-11 |
2016-03-15 |
노파르티스 아게 |
소아 환자의 맥락망막 신생혈관성 및 투과성 장애의 치료에 있어서 vegf 길항제의 용도
|
|
EP2835380B2
(en)
|
2013-07-29 |
2021-04-07 |
Samsung Electronics Co., Ltd |
Method of blocking vascular leakage using an anti-Ang2 antibody
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
US20160252526A1
(en)
|
2013-10-01 |
2016-09-01 |
Sphingotec Gmbh |
A method for predicting the risk of getting a major adverse cardiac event
|
|
PL3062811T3
(pl)
|
2013-11-01 |
2019-10-31 |
Regeneron Pharma |
Interwencje oparte na angiopoetynie do leczenia malarii mózgowej
|
|
EP3116503A4
(en)
|
2014-03-14 |
2017-08-23 |
Aerpio Therapeutics, Inc. |
Hptp-beta inhibitors
|
|
JP2015199733A
(ja)
|
2014-04-04 |
2015-11-12 |
国立大学法人東北大学 |
眼圧降下剤
|
|
US9719135B2
(en)
|
2014-07-03 |
2017-08-01 |
Mannin Research Inc. |
Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
|
|
WO2016022813A1
(en)
|
2014-08-07 |
2016-02-11 |
Aerpio Therapeutics, Inc. |
Combination of immunotherapies with activators of tie-2
|
|
WO2016049183A1
(en)
|
2014-09-24 |
2016-03-31 |
Aerpio Therapeutics, Inc. |
Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
|
|
TWI738632B
(zh)
|
2014-11-07 |
2021-09-11 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|